Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2006;37:440-446
Published online before print January 5, 2006, doi: 10.1161/01.STR.0000199851.24668.f1
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v38,p451)
Right arrow All Versions of this Article:
37/2/440    most recent
01.STR.0000199851.24668.f1v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bateman, B. T.
Right arrow Articles by Pile-Spellman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bateman, B. T.
Right arrow Articles by Pile-Spellman, J.
Related Collections
Right arrow Health policy and outcome research
Right arrow Acute Cerebral Infarction
Right arrow Thrombolysis
Right arrowRelated Article

(Stroke. 2006;37:440.)
© 2006 American Heart Association, Inc.


Original Contributions

Factors Associated With In-Hospital Mortality After Administration of Thrombolysis in Acute Ischemic Stroke Patients

An Analysis of the Nationwide Inpatient Sample 1999 to 2002

Brian T. Bateman; H. Christian Schumacher, MD; Bernadette Boden-Albala, PhD; Mitchell F. Berman, MD, MPH; J.P. Mohr, MD; Ralph L. Sacco, MD, MS John Pile-Spellman, MD

From the Columbia Presbyterian Medical College for Physicians and Surgeons (B.T.B.), Columbia University, New York, NY; Doris and Stanley Tananbaum Stroke Center (H.C.S., B.B.-A., J.P.M., R.L.S.), Neurological Institute, New York Presbyterian Hospital, College of Physicians and Surgeons, Columbia University, New York, NY; Department of Anesthesiology (M.F.B.), College of Physicians and Surgeons, Columbia University, New York, NY; Interventional Neuroradiology (J.P.-S.), Departments of Radiology, Neurology, and Neurosurgery, New York Presbyterian Hospital, College of Physicians and Surgeons, Columbia University, New York, NY; Department of Epidemiology (R.L.S.), Mailman School of Public Health, Columbia University, New York, NY; and Department of Sociomedical Science (B.B.-A.), Mailman School of Public Health, Columbia University, New York, NY.

Correspondence to H. Christian Schumacher, MD, Doris and Stanley Tananbaum Stroke Center, Neurological Institute, New York Presbyterian Hospital, College of Physicians and Surgeons, Columbia University, 710 W 168th St, Box 163, New York, NY 10032. E-mail hs775{at}columbia.edu

Background and Purpose— The prospective trials evaluating the safety and efficacy of intravenous tissue plasminogen activator have generally been conducted at academic medical centers and community hospitals with an institutional commitment to stroke care. Relatively little is known about the safety of this therapy as it is used in the community. We therefore examined outcomes in acute stroke patients treated with thrombolysis using the largest discharge database available in the United States for the years 1999 to 2002.

Methods— Data were derived from the Nationwide Inpatient Sample for the years 1999 to 2002. Using the appropriate International Classification of Disease—Clinical Modification, 9th revision, codes, patients admitted through the emergency room with a primary diagnosis of acute ischemic stroke were selected for analysis. From these patients, those coded as receiving thrombolysis were identified. Multivariate logistic regression was performed on the thrombolysis and nonthrombolysis cohorts to identify independent predictors of in-hospital mortality from among those clinical elements available in the database.

Results— We identified 2594 patients treated with thrombolysis from a group of 248 964 patients admitted through the emergency room with a primary diagnosis of acute ischemic stroke. The thrombolysis cohort had a higher in-hospital mortality rate compared with the nonthrombolysis patients (11.4% versus 6.8%). The rate of intracerebral hemorrhage was 4.4% for the thrombolysis cohort and 0.4% for nonthrombolysis patients. Multivariate logistic regression showed advanced age, Asian/Pacific Islander race, congestive heart failure, and atrial fibrillation/flutter to be independent predictors of in-hospital mortality after thrombolysis. Thrombolysis volume, overall ischemic stroke volume, and teaching status were not significant predictors of in-hospital mortality after thrombolysis.

Conclusions— Thrombolysis, as it is used in the community, has a safety profile that is similar to that observed in the large, prospective clinical trials.


Key Words: stroke, ischemic • thrombolysis


Related Article:

IV Tissue Plasminogen Activator for Stroke in the Community: What We Know and Don’t Know 10 Years After FDA Approval
Anthony J. Furlan
Stroke 2006 37: 281. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Anesth. Analg.Home page
Y. Shen, M. Drum, and S. Roth
The Prevalence of Perioperative Visual Loss in the United States: A 10-Year Study from 1996 to 2005 of Spinal, Orthopedic, Cardiac, and General Surgery
Anesth. Analg., November 1, 2009; 109(5): 1534 - 1545.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Reeves, A. Bhatt, P. Jajou, M. Brown, and L. Lisabeth
Sex Differences in the Use of Intravenous rt-PA Thrombolysis Treatment for Acute Ischemic Stroke: A Meta-Analysis
Stroke, May 1, 2009; 40(5): 1743 - 1749.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
G. Saposnik, T. Jeerakathil, D. Selchen, A. Baibergenova, V. Hachinski, M. K. Kapral, and for the Stroke Outcome Research Canada (SORCan) Wo
Socioeconomic Status, Hospital Volume, and Stroke Fatality in Canada
Stroke, December 1, 2008; 39(12): 3360 - 3366.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. M. Reid, D. Dai, G. J. Gubitz, M. K. Kapral, C. Christian, and S. J. Phillips
Gender Differences in Stroke Examined in a 10-Year Cohort of Patients Admitted to a Canadian Teaching Hospital
Stroke, April 1, 2008; 39(4): 1090 - 1095.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
D. Aujesky MD MSc, M. K. Mor PhD, M. Geng MS, M. J. Fine MD MSc, B. Renaud MD, and S. A. Ibrahim MD MPH
Hospital volume and patient outcomes in pulmonary embolism
Can. Med. Assoc. J., January 1, 2008; 178(1): 27 - 33.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. S. Waikar, G. C. Curhan, J. Z. Ayanian, and G. M. Chertow
Race and Mortality after Acute Renal Failure
J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2740 - 2748.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. Saposnik, A. Baibergenova, M. O'Donnell, M. D. Hill, M. K. Kapral, V. Hachinski, and On behalf of the Stroke Outcome Research Canada (S
Hospital volume and stroke outcome: Does it matter?
Neurology, September 11, 2007; 69(11): 1142 - 1151.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Castellanos, T. Sobrino, M. Millan, M. Garcia, J. Arenillas, F. Nombela, D. Brea, N. Perez de la Ossa, J. Serena, J. Vivancos, et al.
Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Study
Stroke, June 1, 2007; 38(6): 1855 - 1859.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
T. Kurth, P. U. Heuschmann, A. M. Walker, K. Berger, M. L. Flaherty, B. Kissela, P. Khatri, R. M. Dubinsky, and S. M. Lai
Mortality of stroke patients treated with thrombolysis: Analysis of nationwide inpatient sample
Neurology, February 27, 2007; 68(9): 710 - 711.
[Full Text] [PDF]


Home page
NeurologyHome page
L. L. Edwards
Using tPA for acute stroke in a rural setting
Neurology, January 23, 2007; 68(4): 292 - 294.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. J. Furlan
IV Tissue Plasminogen Activator for Stroke in the Community: What We Know and Don't Know 10 Years After FDA Approval
Stroke, February 1, 2006; 37(2): 281 - 281.
[Full Text] [PDF]